Chiasma Inc (NASDAQ:CHMA) Director Roni Mamluk sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $5.31, for a total value of $53,100.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at $53,100. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Roni Mamluk also recently made the following trade(s):

  • On Tuesday, March 5th, Roni Mamluk sold 5,000 shares of Chiasma stock. The shares were sold at an average price of $5.00, for a total value of $25,000.00.
  • On Tuesday, January 22nd, Roni Mamluk sold 5,000 shares of Chiasma stock. The shares were sold at an average price of $3.67, for a total value of $18,350.00.

Shares of NASDAQ CHMA opened at $5.85 on Thursday. Chiasma Inc has a twelve month low of $1.20 and a twelve month high of $7.19. The company has a market cap of $142.91 million, a price-to-earnings ratio of -4.57 and a beta of 1.49.

Chiasma (NASDAQ:CHMA) last posted its earnings results on Friday, March 8th. The biotechnology company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32). Equities analysts forecast that Chiasma Inc will post -1.24 EPS for the current year.

A number of analysts have recently commented on the company. HC Wainwright assumed coverage on Chiasma in a report on Thursday, February 14th. They issued a “buy” rating and a $11.00 price target on the stock. Roth Capital initiated coverage on Chiasma in a research report on Tuesday, February 19th. They issued a “buy” rating and a $16.00 target price on the stock. Cantor Fitzgerald initiated coverage on Chiasma in a research report on Thursday, March 7th. They issued an “overweight” rating and a $5.84 target price on the stock. Brookline Capital Management reaffirmed a “buy” rating on shares of Chiasma in a research report on Wednesday, February 6th. Finally, ValuEngine downgraded Chiasma from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Five analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $10.95.

Several institutional investors have recently bought and sold shares of CHMA. Dimensional Fund Advisors LP increased its holdings in Chiasma by 51.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 80,986 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 27,505 shares in the last quarter. Citadel Advisors LLC increased its holdings in Chiasma by 100.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,656 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 17,881 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Chiasma by 20.9% during the 3rd quarter. Renaissance Technologies LLC now owns 82,700 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 14,300 shares in the last quarter. Vanguard Group Inc. increased its holdings in Chiasma by 42.8% during the 3rd quarter. Vanguard Group Inc. now owns 324,625 shares of the biotechnology company’s stock valued at $1,169,000 after purchasing an additional 97,272 shares in the last quarter. Finally, Vanguard Group Inc increased its holdings in Chiasma by 42.8% during the 3rd quarter. Vanguard Group Inc now owns 324,625 shares of the biotechnology company’s stock valued at $1,169,000 after purchasing an additional 97,272 shares in the last quarter. 64.47% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Chiasma Inc (CHMA) Director Roni Mamluk Sells 10,000 Shares” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/chiasma-inc-chma-director-roni-mamluk-sells-10000-shares/2971356.html.

Chiasma Company Profile

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Featured Article: Do back-end load funds outperform no-load funds?

Insider Buying and Selling by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.